Habif D V, Ozzello L, De Rosa C M, Cantell K, Lattes R
Department of Surgery, Columbia University, New York, New York.
Cancer Invest. 1995;13(2):165-72. doi: 10.3109/07357909509011686.
Two groups of patients with disseminated breast carcinomas who had failed radiotherapy, chemotherapy, and hormonotherapy were treated with natural interferon alpha (nIFN-alpha) alone or in combination with nIFN-gamma delivered in cycles of 10-12 intralesional (i.l.) injections to recurrent and metastatic lesions. In group, I, 16 skin lesions in 12 patients received nIFN-alpha alone resulting in 7 complete regressions verified histologically (CR), 7 partial regressions (PR), and no regressions (NR) in 2. Group II included 4 patients in whom 7 cutaneous recurrences were treated with nIFN-alpha/nIFN-gamma (5 CR, 2 PR), 2 were injected with nIFN-alpha alone (1 CR, 1 PR), and 1 received nIFN-gamma alone (PR). Two additional patients in group II were given i.l. injections of nIFN-alpha/nIFN-gamma to lymph node metastases (1 CR, 1 PR). Clinical toxicity was experienced by 5 of 12 patients in group I and by all the patients in group II and was controlled in most instances by antipyretics. Systemic antitumor effects were not appreciable clinically. Nevertheless, noninjected lesions exposed only to systemic levels of IFNs, when studied immunohistochemically, displayed an immunological response similar to that of IFN-injected lesions, although less intense. Therefore, IFNs can be useful in controlling locoregional recurrences of breast cancer even in patients who are not responding to other forms of therapy. Furthermore, in addition to the local antitumor actions, they appear to be capable of eliciting systemic immunological effects.
两组患有播散性乳腺癌且放疗、化疗和激素治疗均失败的患者,接受单独使用天然干扰素α(nIFN-α)或与天然干扰素γ联合治疗,对复发和转移病灶进行10 - 12次瘤内(i.l.)注射为一个周期。在第一组中,12例患者的16个皮肤病变单独接受nIFN-α治疗,组织学证实7例完全缓解(CR),7例部分缓解(PR),2例无缓解(NR)。第二组包括4例患者,其中7个皮肤复发灶接受nIFN-α/nIFN-γ治疗(5例CR,2例PR),2例单独注射nIFN-α(1例CR,1例PR),1例单独接受nIFN-γ治疗(PR)。第二组另外2例患者对淋巴结转移灶进行瘤内注射nIFN-α/nIFN-γ(1例CR,1例PR)。第一组12例患者中有5例出现临床毒性,第二组所有患者均出现临床毒性,大多数情况下通过退烧药控制。临床上未观察到明显的全身抗肿瘤作用。然而,当通过免疫组织化学研究时,仅暴露于全身水平干扰素的未注射病灶显示出与注射干扰素病灶相似的免疫反应,尽管强度较弱。因此,即使对其他治疗形式无反应的患者,干扰素也可用于控制乳腺癌的局部复发。此外,除了局部抗肿瘤作用外,它们似乎还能够引发全身免疫效应。